Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.69 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.55 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205605 | 0.95 | LMNA (0.75) | FFAR1FFAR4LMNAL3MBTL1SLC5A1 | |
| SCHEMBL456459 | 0.87 | FFAR1 (0.67) | FFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL4652283 | 0.85 | FFAR1 (0.69) | FFAR1FFAR4LMNAL3MBTL1AKR1B1 | |
| SCHEMBL15374821 | 0.85 | FFAR1 (0.69) | FFAR1FFAR4LMNAL3MBTL1AKR1B1 | |
| SCHEMBL28222556 | 0.85 | LMNA (0.61) | FFAR1FFAR4LMNAL3MBTL1SLC5A1 | |
| SCHEMBL7337576 | 0.84 | L3MBTL1 (0.75) | FFAR1LMNAL3MBTL1TP53 | |
| SCHEMBL12000868 | 0.84 | CYP4F2 (0.64) | FFAR1FFAR4LMNAL3MBTL1SLC5A1 | |
| SCHEMBL469864 | 0.84 | LMNA (0.53) | FFAR1FFAR4LMNAL3MBTL1SLC5A1 | |
| SCHEMBL13498531 | 0.83 | FFAR1 (0.60) | FFAR1FFAR4LMNAL3MBTL1SLC5A1 | |
| SCHEMBL469914 | 0.83 | RXRA (0.63) | FFAR1FFAR4LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012032014-A1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | FFAR1 4197/4885FFAR4 3442/4885LMNA 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.